So far, endocrine treatments of ER + BC rely on estrogens deprivation, by inhibiting HA, or on small molecule regulators of ERα, such as selective ERα modulators (SERMs) or downregulators (SERDs). The gene discussed is ERAS; the disease is breast cancer.